Imprime PGG (PGG beta-glucan) - Biothera Pharma
Keytruda (pembrolizumab) - Merck (MSD)
Imprime PGG + Keytruda: "Imprime PGG in combination with pembrolizumab shows promising clinical benefit in previously-treated, metastatic TNBC patients"; Triple negative breast cancer (Biothera) - Jun 2, 2019 - ASCO 2019: "Clinical response is evident as early as 6 weeks on treatment" 
P2 data
https://www.biothera.com/wp-content/uploads/2019/05/Biothera-Pharmaceuticals-ASCO19-mTNBC-poster-52819.pdf
 
Jun 2, 2019
 
 
0604ccf9-1838-482a-ab1b-f07f1a61b810.jpg

36e7fcb3-a62d-457b-b05f-f7c7eed845b5.jpg

8f9a890c-4ecc-467d-b213-8a2a9a8d6006.jpg